RESUMO
Melanoma causes substantial burden of medical costs and years of life lost. Wide variations in melanoma diagnosis and treatment have been identified at least in the United States, Australia, Germany, Italy and France [1]. The variation especially in the quality of reporting on pathological specimens has been reported. The aim of this retrospective study was to assess the impact of expert pathology review of melanoma on the staging and thus treatment decisions in cutaneous melanoma patients in a multidisciplinary tumor board. A total of 567 patients were referred to the multidisciplinary meeting with a diagnosis of new invasive or in situ melanoma from 14.10.2014 to 31.5.2018. Among these patients, a second expert histopathologic review resulted in changes in interpretation for 46 out of 567 (8%) patients. Of patients originally diagnosed with melanoma, pathologic review led to a change in diagnosis to benign lesions in 19 cases. The Breslow thickness changed >0.3â¯mm in 22 cases leading changes in staging and thus treatment. Minor changes (≤0.3â¯mm) in Breslow thickness was found in 5 cases. Our data suggest that review of melanoma by an expert dermatopathologist results in frequent, clinically meaningful alterations in diagnosis, staging and surgical treatment. The confirmation of a cancer diagnosis should be the first step in the initiation of multidisciplinary monitoring especially in patients younger than 40 years old and early-stage tumors.
